European panel recommends Lilly's GLP-1 pill, plus three drugs
The European Medicines Agency's human medicines committee has endorsed Eli Lilly's oral GLP-1 pill orforglipron and three other new drugs. Lilly is aiming to compete with Novo Nordisk's oral Wegovy. The recommendation is a step toward EU approval.
The European Medicines Agency's human medicines committee has backed Eli Lilly's orforglipron, an oral GLP-1 pill, along with three additional new medicines. The recommendation is a regulatory milestone that could move these products closer to authorization in the European Union. Lilly is positioning orforglipron to compete with Novo Nordisk's oral Wegovy. The recommendation does not itself grant marketing approval; it is one step in the review process.
If the recommendation leads to EU authorization, patients and prescribers could gain another oral GLP-1 option, potentially broadening choice. Greater competition between Lilly and Novo Nordisk may influence pricing, access, and treatment decisions over time. Health systems and payers could also weigh coverage and demand. The panel's action alone does not ensure availability; final regulatory decisions and market launch timing remain uncertain.